Behind The Success - Research Report on Corcept Therapeutics Inc. and Dyax Corp.

  Behind The Success - Research Report on Corcept Therapeutics Inc. and Dyax
                                    Corp.

Biotech firms Corcept and Dyax have each risen to the occasion with their
innovative solutions for unmet medical needs, both having gained substantial
momentum as of late

PR Newswire

NEW YORK, January 23, 2013

NEW YORK, January 23, 2013 /PRNewswire/ --

After a less than satisfying launch of its flagship product Korlym - a
treatment for Cushing's syndrome - resulting in a sharp drop in the stock
price, drug developer Corcept Therapeutics Inc. (NASDAQ:CORT) [Full Research
Report]^[1] has bounced back with an influx of buyers and renewed sentiment
from analysts.

The company's stock price fell more than half in November last year from $2.50
to just $1.32 as sales of Korlym underperformed due to subpar marketing.
Losses reached up to a whopping $8.3 million and only turned sales at less
than $2 million. This year, the price rallied back up to $2 with a price
target of $3 and was given a "buy" rating from Janney Capital.

Korlym is so far the only available drug for Cushing's syndrome patients in
the market, and is granted orphan drug status by the FDA - giving it an
additional two years of exclusivity on the market. This mainly triggered the
interest of investors, who helped raise Corcept's stock price to as high as
$4.90 in early 2012.

Dyax Corp. (NASDAQ:DYAX) [Free Research Report]^[^2^], a developer of Kalbitor
- a drug that treat patients with hereditary angioedema (HAE) - has been
downgraded by Zacks to a "neutral" rating from "outperform." The stock price
is up by close to 2 percent at $3.65, and has a target price of $3.90.

The company recently updated Kalbitor (aka ecallantide) data from both HAE
patients and HAE patients with abdominal attacks. The drug is indicated for
the treatment of acute attacks of HAE in patients 16 years of age and older.
Its approval is based on the results of two placebo-controlled Phase 3
clinical studies, known as EDEMA3 and EDEMA4. Patients having an HAE attack at
any part of the body, with at least one moderate or severe symptom, are
treated with 30 mg subcutaneous KALBITOR or placebo.

Reference Links:

^[1] ^ The Full Research Report on Corcept Therapeutics Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/fc48_CORT]

^[^2^] ^ The Free Research Report on Dyax Corp. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/6a05_DYAX]

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop -- long before they become
the next top news on major financial networks.

Contact: Demi Lapierre
Email: press@NationalTradersAssociation.org
Main: +1-(702)-212-4493

SOURCE National Traders Association